{
  "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac",
  "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e",
  "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 30,
  "pageCount": 49,
  "prevPage": 29,
  "nextPage": 31,
  "slideType": "key_messages",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide uses a combination of scientific evidence (left) and market/trial status (right) to justify investment.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/30",
  "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac",
  "deckJsonHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac.json",
  "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-30",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 1,
        "x": 0,
        "y": 0.82
      },
      "kind": "callout",
      "text": "PoC data will inform Phase III investment decision for either Ultomiris, ALXN1720 or ALXN2050",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b88e5d32-8fa6-4324-9c4e-2ce2806944ab",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.35,
        "x": 0.03,
        "y": 0.025
      },
      "kind": "list",
      "text": "Evidence for the role of alternative and terminal pathways in IgAN: Increased levels of C3 proteolytic fragments, Urinary C5b-9 elevated, In-human PoC presented.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c104f817-9ff7-466d-841f-5be8ff9ecda9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.8,
        "x": 0.03,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "1. Renal class III-IV, with or without class V. IgAN = IgA nephropathy; LN = lupus nephritis; PoC = proof-of-concept; EU5 = France, Germany, Italy, Spain, United Kingdom; FPCD = first patient commenced dosing.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a0925845-9ec2-4829-9b11-32304b156103",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.55,
        "x": 0.4,
        "y": 0.025
      },
      "kind": "table",
      "text": "PoC trials with Ultomiris and ALXN2050 in renal indications: Diagnosed patients (>250k IgAN, >130k LN), Treatment landscape (unmet need), Trial status (enrollment progress).",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a447efb0-57d4-466c-8360-b3e5d88b5585",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Complement inhibition in renal represents potential multi-blockbuster opportunity",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a21508bd-7ee1-45bb-8432-5217b1bea225",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Alexion portfolio approach in IgAN and LN",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "06952651-5df4-427c-b9f3-0612606c4efd",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 49,
      "from": 30,
      "beatId": "b1684c82-ee88-4ad4-93d8-997135e543e9",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "The document outlines the potential impact of AstraZeneca's medicines and next steps for the company",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}